Corxel Pharmaceuticals will list on Nasdaq via Amanat Acquisition Corp in a deal targeting $377M. Read how this ...
Merck's sac-TMT met both primary endpoints in Phase III TroFuse-005 for advanced endometrial cancer and is heading to FDA ...
Incyte's INCB161734 KRAS G12D inhibitor posted 89% and 81% objective response rates in Phase I PDAC and CRC data at ESMO 2026 ...
Kelun-Biotech's final OS analysis of Phase III OptiTROP-Lung04 shows sac-TMT extended median overall survival in lung cancer.
HUTCHMED's SAFFRON trial shows savolitinib plus osimertinib met its Phase III goal in lung cancer, and a US filing has been ...
Iza-bren doubled progression-free survival vs chemotherapy in EGFR-mutated NSCLC in the Phase III PANKU LUNG-01 study. Read the full trial results now.
Researchers built a shark-antibody toxin that kills ERα36 breast cancer cells and shrinks tumors in mice. Human efficacy is ...
Roche's sefaxersen met its Phase III IMAgINATION trial endpoint, cutting proteinuria 43.1% vs placebo in IgA nephropathy.
DYNASTY-Breast02 met its primary endpoint for trastuzumab pamirtecan in HER2-low breast cancer, but companies flag limited ...
Tango Therapeutics (Nasdaq: TNGX) reported an 82% objective response rate (ORR) for vopimetostat plus daraxonrasib in previously treated... China-based Sichuan Kelun-Biotech Biopharmaceutical (HKEX: ...
Novartis' oral BTK inhibitor remibrutinib (Rhapsido) met its primary endpoint in Phase III REMODEL-1 and REMODEL-2 relapsing ...
BioNTech and Bristol-Myers Squibb report a 36.7% confirmed response rate for pumitamig in advanced NSCLC after immunotherapy. Read the Phase 2 details now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results